Growth Metrics

Journey Medical (DERM) Equity Ratio (2020 - 2026)

Journey Medical filings provide 6 years of Equity Ratio readings, the most recent being 0.34 for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 34.64% to 0.34 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.34, a 34.64% increase, with the full-year FY2025 number at 0.34, up 34.64% from a year prior.
  • Equity Ratio hit 0.34 in Q4 2025 for Journey Medical, up from 0.3 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.43 in Q4 2021 to a low of 0.13 in Q3 2021.
  • Median Equity Ratio over the past 5 years was 0.25 (2022), compared with a mean of 0.22.
  • Biggest five-year swings in Equity Ratio: plummeted 99.98% in 2023 and later skyrocketed 241594.88% in 2024.
  • Journey Medical's Equity Ratio stood at 0.43 in 2021, then plummeted by 62.63% to 0.16 in 2022, then skyrocketed by 63.98% to 0.26 in 2023, then decreased by 5.55% to 0.25 in 2024, then skyrocketed by 34.64% to 0.34 in 2025.
  • The last three reported values for Equity Ratio were 0.34 (Q4 2025), 0.3 (Q3 2025), and 0.24 (Q2 2025) per Business Quant data.